Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18338533 | 1.00 | DRD2 (0.36) | DRD2DRD4DRD3RECQLGAA | |
| SCHEMBL18338645 | 0.80 | — | — | |
| SCHEMBL25951094 | 0.78 | DRD2 (0.35) | DRD2DRD4DRD3 | |
| SCHEMBL26114431 | 0.77 | DRD2 (0.33) | DRD2DRD4DRD3 | |
| SCHEMBL25950754 | 0.77 | DRD2 (0.40) | DRD2DRD4DRD3 | |
| SCHEMBL18338606 | 0.77 | DRD2 (0.34) | DRD2DRD4DRD3 | |
| SCHEMBL24566440 | 0.77 | DRD2 (0.34) | DRD2DRD4DRD3 | |
| SCHEMBL30406244 | 0.74 | CYP1A2 (0.32) | DRD2DRD4DRD3 | |
| SCHEMBL21626241 | 0.70 | RECQL (0.30) | RECQL | |
| SCHEMBL18338393 | 0.69 | DRD2 (0.54) | DRD2DRD4DRD3RECQLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017539-A1 | TRI-HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017539-A1 | TRI-HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND USE THEREOF | JAK2, JAK1, JAK3 | DRD2 3757/4885DRD4 4393/4885DRD3 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.